EGFR and non-small cell lung carcinoma: Afatinib (BIBW 2992, USA: GilotrifTM, other countries: Giotrif©) is an ErbB family irreversible blocker that was authorized by the FDA and EMA in 2013 for the treatment of advanced EGFR mutation-positive NSCLC [20].